Glycogen synthase kinases‐3β controls differentiation of malignant glioma cells

Malignant gliomas persist as a major disease of morbidity and mortality in adult. Differentiation therapy has emerged as a promising candidate modality. However, the mechanism related is unknown. Here, we show that glycogen synthase kinase‐3β (GSK‐3β) is highly expressed and activated during the cholera toxin‐induced differentiation in sensitive C6 and U87‐MG malignant glioma cells, whereas the GSK‐3α activity remains stable. GSK‐3β inhibitors or small interfering RNA suppress the induced‐differentiation in sensitive C6 cells. Conversely, overexpression of a constitutively active form of human GSK‐3β (pcDNA3‐GSK‐3β‐S9A) mutant in resistant U251 glioma cells restores their differentiation capabilities. In addition, GSK‐3β triggers cyclin D1 nuclear export and subsequent degradation, which is necessary for differentiation in C6 and U251 glioma cells. Analysis of human glioma tissues further revealed overexpression of active GSK‐3β. These findings suggest that GSK‐3β is a differentiation fate determinant, and shed new lights on the mechanism by which GSK‐3β regulates cyclin D1 degradation and cellular differentiation in gliomas.

[1]  M. Garrett,et al.  Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis , 2005, Oncogene.

[2]  D. Nelson,et al.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.

[3]  S. Shurtleff,et al.  Monoclonal antibodies to mammalian D-type G1 cyclins. , 1994, Hybridoma.

[4]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[5]  A. Kimmel,et al.  GSK3, a master switch regulating cell-fate specification and tumorigenesis. , 2000, Current opinion in genetics & development.

[6]  Claus Scheidereit,et al.  NF-κB Function in Growth Control: Regulation of Cyclin D1 Expression and G0/G1-to-S-Phase Transition , 1999, Molecular and Cellular Biology.

[7]  M. Roussel,et al.  Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.

[8]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.

[9]  A. Xu,et al.  Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. , 2006, Cancer research.

[10]  Chenguang Wang,et al.  Minireview: Cyclin D1: normal and abnormal functions. , 2004, Endocrinology.

[11]  J. Moss,et al.  Activation of adenylate cyclase by choleragen. , 1979, Annual review of biochemistry.

[12]  S. Safe,et al.  Peroxisome Proliferator-activated Receptor γ Agonists Induce Proteasome-dependent Degradation of Cyclin D1 and Estrogen Receptor α in MCF-7 Breast Cancer Cells , 2003 .

[13]  R. Jope,et al.  The glamour and gloom of glycogen synthase kinase-3. , 2004, Trends in biochemical sciences.

[14]  R. Urrutia,et al.  Glycogen Synthase Kinase-3β Participates in Nuclear Factor κB–Mediated Gene Transcription and Cell Survival in Pancreatic Cancer Cells , 2005 .

[15]  H. Larjava,et al.  HaCaT keratinocyte migration is dependent on epidermal growth factor receptor signaling and glycogen synthase kinase-3alpha. , 2006, Experimental cell research.

[16]  Christina A. Wilson,et al.  GSK-3α regulates production of Alzheimer's disease amyloid-β peptides , 2003, Nature.

[17]  P. Fisher,et al.  Differentiation therapy of human cancer: basic science and clinical applications. , 2001, Pharmacology & therapeutics.

[18]  S. Pastorino,et al.  Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. , 2008, Cancer research.

[19]  J. Woodgett,et al.  cDNA cloning and properties of glycogen synthase kinase-3. , 1991, Methods in enzymology.

[20]  H. Zoghbi,et al.  The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1 , 1997, Nature.

[21]  K. Kawakami,et al.  Potential Therapeutic Effect of Glycogen Synthase Kinase 3β Inhibition against Human Glioblastoma , 2009, Clinical Cancer Research.

[22]  M. Fountoulakis,et al.  Is current therapy of malignant gliomas beneficial for patients? Proteomics evidence of shifts in glioma cells expression patterns under clinically relevant treatment conditions , 2006, Proteomics.

[23]  R. Urrutia,et al.  Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. , 2005, Cancer research.

[24]  Hideki Yamamoto,et al.  Complex Formation of Adenomatous Polyposis Coli Gene Product and Axin Facilitates Glycogen Synthase Kinase-3β-dependent Phosphorylation of β-Catenin and Down-regulates β-Catenin* , 2000, The Journal of Biological Chemistry.

[25]  E. Appella,et al.  GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. , 2008, Cancer cell.

[26]  J. Woodgett,et al.  Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. , 2000, Nature.

[27]  J. Diehl.  Cycling to Cancer with Cyclin D1 , 2002, Cancer biology & therapy.

[28]  P. Cohen,et al.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.

[29]  A. Harwood,et al.  Regulation of GSK-3 A Cellular Multiprocessor , 2001, Cell.

[30]  R. Goold,et al.  Microtubule-associated protein 1B phosphorylation by glycogen synthase kinase 3beta is induced during PC12 cell differentiation. , 2001, Journal of cell science.

[31]  宮下 勝吉.  Potential therapeutic effect of glycogen synthase kinase 3β inhibition against human glioblastoma , 2009 .

[32]  P. Nurse.  A Long Twentieth Century of the Cell Cycle and Beyond , 2000, Cell.

[33]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[34]  Peter Lichter,et al.  Amplification and Expression of Cyclin D Genes (CCND1 CCND2 and CCND3) in Human Malignant Gliomas , 1999, Brain pathology.

[35]  M. Adamo,et al.  Cyclic AMP Inhibits Extracellular Signal-regulated Kinase and Phosphatidylinositol 3-Kinase/Akt Pathways by Inhibiting Rap1* , 2001, The Journal of Biological Chemistry.

[36]  U. Rapp,et al.  Cell cycle targets of Ras/Raf signalling , 1998, Oncogene.

[37]  Jun Qin,et al.  Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. , 2005, Molecular cell.

[38]  J L Cleveland,et al.  Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. , 2000, Genes & development.

[39]  J W Yates,et al.  Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. , 2000, Chemistry & biology.

[40]  F. Zindy,et al.  Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. , 1997, Genes & development.

[41]  Yan Li,et al.  Cholera toxin induces malignant glioma cell differentiation via the PKA/CREB pathway , 2007, Proceedings of the National Academy of Sciences.

[42]  P. Carlsson,et al.  Wnt-signalling pathway in ovarian epithelial tumours: increased expression of β-catenin and GSK3β , 2003, British Journal of Cancer.

[43]  J. Woodgett,et al.  Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation , 2000, Nature.

[44]  C. Croce,et al.  Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Jope,et al.  The multifaceted roles of glycogen synthase kinase 3β in cellular signaling , 2001, Progress in Neurobiology.

[46]  Zhiwei Wang,et al.  Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. , 2007, The Journal of biological chemistry.

[47]  Charles J. Sherr,et al.  Mammalian G1 cyclins , 1993, Cell.

[48]  J. Downward,et al.  Role of phosphoinositide-3-OH kinase in Ras signaling. , 1997, Advances in second messenger and phosphoprotein research.

[49]  P. Cohen,et al.  The renaissance of GSK3 , 2001, Nature Reviews Molecular Cell Biology.

[50]  Zhiwei Wang,et al.  Regulation of FOXO3a/β-Catenin/GSK-3β Signaling by 3,3′-Diindolylmethane Contributes to Inhibition of Cell Proliferation and Induction of Apoptosis in Prostate Cancer Cells* , 2007, Journal of Biological Chemistry.

[51]  G. Kapoor,et al.  Mitogenic signaling cascades in glial tumors. , 2003, Neurosurgery.

[52]  P. Shaw,et al.  Expression analysis of glycogen synthase kinase-3 in human tissues. , 1999, The journal of peptide research : official journal of the American Peptide Society.

[53]  B. Doble,et al.  GSK-3: tricks of the trade for a multi-tasking kinase , 2003, Journal of Cell Science.

[54]  A. Robles,et al.  Induction of cyclin D1 overexpression by activated ras. , 1994, Oncogene.

[55]  H. Koh,et al.  Cyclic AMP Inhibits Akt Activity by Blocking the Membrane Localization of PDK1* , 2001, The Journal of Biological Chemistry.

[56]  Jun Qin,et al.  Erk Associates with and Primes GSK-3β for Its Inactivation Resulting in Upregulation of β-Catenin , 2005 .

[57]  F. McCormick,et al.  Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. , 1999, Nature.

[58]  S. Ng,et al.  Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells , 1995, Molecular and cellular biology.

[59]  Christina A. Wilson,et al.  GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. , 2003, Nature.

[60]  A. Goldberg,et al.  Proteasome inhibitors: valuable new tools for cell biologists. , 1998, Trends in cell biology.